Background: Antihypertensive treatment is based on randomized controlled trials (RCTs) started since 1966. Meta-analyses comprehensive of all RCTs but limited to RCTs investigating blood pressure (BP) lowering in hypertensive patients are lacking.
INTRODUCTION

H
ypertension is an area of cardiovascular medicine, in which evidence in favor of therapeutic intervention was searched by randomized controlled trials (RCTs) long before the same methodology was applied to the treatment of other cardiovascular illnesses, such as myocardial infarction and heart failure [1] . Consequently, there have been a number of overviews and meta-analyses of antihypertensive drug trials, starting from the seminal meta-analysis by Collins et al. [2] , which have been instrumental to confirm and help quantifying the cardiovascular-disease-preventing effects of blood pressure (BP)-lowering treatment [3] [4] [5] [6] .
Evidence on the effects of BP lowering on different types of fatal and nonfatal cardiovascular outcomes largely relies upon the placebo-controlled trials, many of which were completed before 2000 and were included in the earlier meta-analyses [2] [3] [4] . A considerable number of placebo-controlled trials and trials of more or less intense BP lowering have been added recently and have not been covered by the existing overviews. Furthermore, metaanalyses of antihypertensive treatment RCTs have included all trials that have used antihypertensive agents even in individuals without hypertension [4, 5] and in cardiovascular conditions, such as acute myocardial infarction and heart failure [6] , in which drugs with antihypertensive activity were used to investigate the mechanisms of their potential benefits and in which benefits of antihypertensive drugs may be independent of BP lowering. The importance of restricting the analyses to RCTs on hypertensive individuals has been recently underlined by the panel members appointed to the Eighth Joint National Committee (JNC 8) [7] , who have done a critical overview but no metaanalyses.
We have done a comprehensive overview of antihypertensive treatment RCTs from their inception in 1966-2013, and carried out a series of meta-analyses and metaregression analyses to approach the problems listed above. This article reports the results of analyses quantifying the relative and absolute effects of BP lowering on different types of cardiovascular outcomes, and investigating the effects of BP reductions of different extent.
METHODS
Trial eligibility
The present overview intended to include all RCTs of BPlowering drugs, in which active drugs were compared with placebo or no treatment with the intention to investigate the consequences of BP differences (intentional BP-lowering trials, placebo controlled); a more intense BP lowering was compared with a less intense one (intentional BP-lowering trials, more or less intense); or BP-lowering drugs were compared with placebo and a between-group difference of at least 2 mmHg in either SBP or DBP occurred, though the design of the trials was not that of investigating the effects of BP differences (nonintentional BP-lowering trials).
In addition, trials had to meet the following predetermined criteria: enrolling individuals with hypertension (SBP !140 or DBP !90 mmHg or current antihypertensive drugs) or a proportion of at least 40% hypertensive individuals among those randomized, with exclusion of trials investigating acute myocardial infarction, heart failure, acute stroke and patients on dialysis; protocol including measurement of at least one type of cardiovascular events as primary or secondary endpoints; BP values measured at baseline and follow-up; follow-up of at least 6 months; a minimum of five events during follow-up; randomized allocation to treatments; and publication within 31 December 2013. In order to make the overview as comprehensive as possible, no other inclusion criteria were prespecified.
The database search was done by two of the authors (C.T. and A.Z.) by consulting PubMed between 1966 and end of December 2013 (any language), the Cochrane Collaboration Library database, and the reference lists of all major previous meta-analyses and overviews of antihypertensive treatment trials [3] [4] [5] [6] . Whenever possible, in case of doubt or missing information, the trial authors were consulted. Recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement [8] were adhered to.
Outcomes
Data on seven predetermined outcomes were extracted: stroke (fatal and nonfatal); coronary heart disease (CHD) events (coronary death and nonfatal myocardial infarction); hospitalized heart failure; major cardiovascular events, composite of stroke and CHD; major cardiovascular events, composite of stroke, CHD, and heart failure; cardiovascular death; and all-cause death. The definition of outcomes reported in the original article was retained, but whenever possible transient ischemic attacks, angina, revascularization procedures, and nonhospitalized nonfatal heart failure were excluded. Two authors (C.T. and A.Z.) independently extracted the data, with differences resolved by discussion.
Quality assessment
Selection, detection, and attrition bias were assessed based on the randomization procedure, method of blinding, and combined evaluation of lost to follow-up and therapy discontinuation ratio. Studies of higher quality were those reporting randomization generation sequence, with double blinding, and lost to follow-up ratio less than 10%, accompanied by therapy discontinuation less than 10% per year of follow-up. We also arbitrarily assigned higher quality to studies with at least 60% of hypertensive individuals prevalence at baseline and to studies with at least 5000 patientyears. Moreover, we evaluated the number of outcomes reported in each individual trial, with those reporting four or more types of outcome being of higher quality compared with those reporting less than 4. The evaluation and scoring of the above six criteria were based on a binomial integer scale ranging from 0 to 1, with 1 being better. These scores were summed-up and reflected the overall study quality, with six being the best. Our quality assessment was not substantially different from that proposed by the Cochrane Collaboration's tool to assess the risk of bias; however, our modified procedure further aims at evaluating the extent of hypertension prevalence among studies, integrates specific additional criteria of bias beyond randomization and blindness, and finally takes into account the magnitude of the product 'patient-years'.
Statistical analyses
We did separate analyses of different groups of RCTs: placebo-controlled trials of intentional BP lowering; intentional BP-lowering trials comparing more with less intense treatment; and nonintentional BP-lowering trials. We also analyzed groups 1 and 2 together, both being of intentional BP lowering. This joint analysis was predetermined as the primary objective of the meta-analyses. In a secondary type of analyses, the three groups of trials were meta-analyzed together.
All analyses were done using the data as tabulated in the original publications. In each group, baseline patient characteristics and SBP/DBP differences between randomized treatments were the means of every individual trial values weighted by patients' number and follow-up duration. For every group of comparison, the null hypothesis of no difference between randomized treatments (active or more active versus placebo or less active) was tested for each of the outcomes. Relative risk (RR) estimates [with 95% confidence interval (CI)] were combined using a random-effect model, in which the log RR for every trial was weighted by the reciprocal of the variance of the log RR. The proportion of inconsistency across the studies not explained by chance was quantified with the I 2 statistics. Whenever no significant heterogeneity was detected by the X 2 Q statistics (P > 0.05), a fixed-effect model was also implemented.
Risk ratios and their 95% CI were reported using the Mantel-Haenszel method, and the effects of BP lowering on each outcome were illustrated with the forest plots under the random-effects model. Risk estimates were standardized to a difference of 10 mmHg SBP and 5 mmHg DBP by multiplying the RR estimate in each trial by the appropriate factor after having considered the effect of the inverse variance of individual trials. Five-year absolute risk reductions (weighted for follow-up period inverse variance and sample size) of standardized BP-lowering treatment were also calculated as well as the number of patients needed to treat (NNT) for 5 years to prevent one outcome. Random-effect meta-regression models with inverse variance weighting were constructed to explore whether the achieved BP difference (independent variable) between the randomized groups explained the variance of RR estimates for various outcomes. Meta-regressions versus SBP reductions were also calculated after adjustment for DBP reductions and vice versa. In order to correct for the different levels of control BP, meta-regressions were also calculated by expressing SBP, DBP, and pulse pressure (PP) reductions as percentages of respective values in the control groups.
The presence of publication bias was investigated graphically by the funnel plots of precision (random effect plotting) and the Duval and Tweedie trim-and-fill method.
All statistical analyses were done using the Comprehensive Meta Analysis version 2 (Biostat, Englewood, New Jersey, USA). In each individual analysis, a P value less than 0.05 was considered to indicate statistical significance; however, this statistical threshold should be interpreted with caution because multiple comparisons were performed. Figure 1 illustrates the investigational steps to identify trials to be included. Searching strategy is indicated in online Supplemental Table S1 , http://links.lww.com/HJH/A412, and trials excluded are listed in online Supplemental Table S2 , http://links.lww.com/HJH/A412. This procedure identified 68 eligible trials. All trials were randomized, with the only exception of the Systolic Hypertension in China (SystChina) trial, in which treatment assignment was by alternate allocation. This trial was included because its design was parallel to the randomized Systolic Hypertension in Europe (SystEur) trial and the results very similar; what makes bias because of alternate allocation unlikely. The SystChina trial was excluded in the sensitivity analyses excluding low-quality trials. Table 1 shows the characteristics of the 68 trials , with a total of 245 885 participants followed up for a mean of 4.3 years, that is, 1 058 177 patient-years. About 81% of RCTs (55 of 68) were of higher quality (scoring from 4 to 6), with only 19% (13 of 68) of lower quality. Thirty-three trials Effects of blood-pressure-lowering treatment on various outcomes in hypertensive individuals BP differences between treatments were larger in placebo controlled than in more versus less intense BP-lowering trials and nonintentional BP-lowering trials. The risk of each of the seven outcomes was significantly reduced in the first group of trials (Fig. 2a) , whereas only risks of stroke, CHD, and heart failure (limited to the nonintentional group) were significantly reduced in the other two groups of BP-lowering trials ( Fig. 2b and c) . When all intentional BP-lowering trials (primary analysis; Fig. 2d ) and all intentional and nonintentional ones (secondary analysis; Fig. 2e ) were analyzed together, the risk of all outcomes was significantly reduced. In the primary analysis (Fig. 2d) , a standardized lowering of 10 mmHg SBP and 5 mmHg DBP was found to reduce the risk of stroke and heart failure to the greatest In all RCTs in which randomization was to more than two groups, comparisons are between the average of all active treatment groups and placebo [13, 25, 26, 38, 60, 61, 68] or between combination therapy and average of monotherapies [49] . In HOT [50] , comparison is between the groups randomized to DBP target less than 80 versus DBP targets less than 85 and less than 90 mmHg together. BP, blood pressure; NR, not reported. 
RESULTS
Trials and patients
FIGURE 2
Relative and absolute risk reduction of various outcomes in the blood-pressure-lowering trials. Standardized RR is to a SBP/DBP reduction of 10/5 mmHg. The column absolute risk reduction reports the number (and 95% CI) of events prevented every 1000 patients treated for 5 years with a standardized RR. NNT is the number (and 95% CI) of patients needed to treat for 5 years to prevent one event. CHD, coronary heart disease; CI, confidence interval; CV, cardiovascular; HF, heart failure; n, number; NNT, number needed to treat; pts, patients; RR, Mantel-Haenszel risk ratios; vs., versus.
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Relationships of different outcome reductions to the extent of blood pressure reductions
Relationships of different outcome reductions to the extent of blood pressure reductions were investigated by the metaregression analyses of 47 trials of intentional BP lowering , that is, those trials specifically designed to explore the effects of BP reduction. The natural logarithm of the risk ratio of stroke was significantly related to the extent of SBP, DBP, and PP reductions, and that of cardiovascular mortality to SBP and PP reductions. For heart failure, relationships with SBP, DBP, and PP reductions fell short of statistical significance, probably because heart failure was reported by fewer trials. Risk ratios of CHD and allcause mortality did not show significant relationships with any BP reduction (Fig. 4) . Risk ratios of the composite outcomes of stroke and CHD, and stroke, CHD, and heart failure both showed significant relationships with all BP reductions. Adjusting meta-regressions of log risk ratios over SBP, DBP, and PP reductions by, respectively, DBP, SBP, and SBP/DBP differences did not change the regression slopes or their statistical significance. Relationships were steeper for stroke and heart failure than for cardiovascular mortality and for DBP than SBP reductions; relationships with PP reductions were intermediate. However, the span of BP reductions was wider for SBP than for DBP and PP (about 40, 25, and 15 mmHg, respectively). When meta-regressions were calculated by using percentage changes in BP, which were similar for SBP, DBP, and PP (maximum reductions of 22, 22, and 25%), regression coefficients were very similar for all types of BP, and stroke risk ratios with maximum achieved SBP, DBP, and PP reductions were, respectively, 0.44, 0.36, and 0.41, and cardiovascular death risk ratios were 0.66, 0.68, and 0.66, respectively (Fig. 5) .
The linear relationships of SBP, DBP, and PP reductions with risk ratio logarithms imply risk ratios decreased to a progressively lower extent at progressively larger BP reductions: for example, stroke risk ratio decreased from 0.88 to 0.72 with a 10 mmHg SBP reduction, from 0.72 to 0.58 with a further 10 mmHg SBP reduction (total reduction 20 mmHg), from 0.58 to 0.48 with a further 10 mmHg SBP reduction (total reduction 30 mmHg), and from 0.48 to 0.39 with an additional 10 mmHg SBP reduction (total 40 mmHg).
Publication bias
For this assessment, reference is made to online Supplemental Figure S2 A-G, http://links.lww.com/HJH/A412 and Table S3 , http://links.lww.com/HJH/A412. Although graphic representations could not exclude publication bias for stroke and heart failure, significant bias was denied by the trim-and-fill method.
DISCUSSION
This overview was aimed at investigating two clinically relevant questions: the extent of the benefits of BP lowering in hypertensive patients, and whether all benefits are proportional to BP reduction and which reduction (SBP, DBP or PP) plays a major role. 
FIGURE 3
Relative and absolute risk reduction of various outcomes in the blood-pressure-lowering trials. Sensitivity analysis including intentional trials exclusively in hypertensive patients.. Standardized RR is to a SBP/DBP reduction of 10/5 mmHg. The column absolute risk reduction reports the number (and 95% CI) of events prevented every 1000 patients treated for 5 years with a standardized RR. NNT is the numbers (and 95% CI) of patients needed to treat for 5 years to prevent one event. CHD, coronary heart disease; CI, confidence interval; CV, cardiovascular; HF, heart failure; n, number; NNT, number needed to treat; pts, patients; RR, Mantel-Haenszel risk ratios.
Extent of the benefits of blood-presurelowering treatment in hypertensive patients
With respect to the two seminal meta-analyses of BP-lowering trials by Collins et al. SBP/DBP difference are remarkably similar in our primary analysis and in the study by Collins and MacMahon [3] (standardized to a 5-6 mmHg DBP difference): 36 versus 38% reduction in stroke, 16 versus 16% reduction in CHD, and 18 versus 21% reduction in cardiovascular death. RR reductions found in our meta-analyses are also rather similar to those reported by Psaty et al. [80] in their meta-analysis including 25 trials, but a close comparison is difficult because it is not clear to which BP differences the Psaty et al.'s risk ratios refer. With respect to the more recent and comprehensive meta-analysis by Law et al. [6] (71 trials), the 68 trials of our overview include 33 trials not considered by Law et al. [12, 24, 30, 33, 43, 44, 46, [48] [49] [50] [51] [52] [53] [54] [55] [57] [58] [59] [60] [61] [62] [63] [65] [66] [67] [68] [69] [70] [71] [72] 74, [76] [77] [78] [79] , 17 of which published after their overview, and are exclusive of all the trials in patients on conditions other than hypertension or in which less than 40% of hypertensive individuals were enrolled. RR reduction of stroke for a standardized 10/5 mmHg SBP/DBP difference was somewhat lower in our primary and secondary meta-analyses (36 versus 41%) and that of CHD also lower in our meta-analyses (16 and 20% versus 22%), suggesting that inclusion of patients with acute CHD or heart failure may inflate the benefit of BP-lowering treatment, possibly through specific effects of drugs in these conditions.
Our primary meta-analysis (Fig. 1d) confirms that stroke and heart failure were the events most effectively prevented by BP lowering (heart failure to an even larger extent than stroke), but also CHD and cardiovascular and all-cause deaths were significantly prevented though to a smaller extent. For 10/5 mmHg SBP/DBP lowering, 17 strokes were avoided every 1000 hypertensive patients treated for 5 years (this means that 58 patients had to be treated for 5 years to prevent 1 stroke), 28 major cardiovascular events (CHD, heart failure) were avoided (this means that 36 patients had to be treated to prevent one event), whereas seven cardiovascular deaths were avoided (this means that 141 patients had to be treated to prevent one cardiovascular death).
Our secondary meta-analysis, comprehensive of intentional and nonintentional BP-lowering RCTs (Fig. 1e) , is entirely consistent with the conclusion of the primary analysis. The greater efficiency of BP lowering in preventing stroke than CHD parallels the well known steeper relationship of BP with stroke than CHD [80] in the observational studies.
Relationships of different outcome reductions to the extent of blood pressure reductions
The relationship between the extent of RR reduction and that of BP reduction has been investigated in the previous meta-regression analyses [4, 6, [82] [83] [84] . However, to our knowledge, ours are not only the most comprehensive ones, but also the first to have searched for a relationship with PP reductions. The finding that PP, often considered a sign of more advanced vascular disease, was not in closer relationship with cardiovascular outcomes may be taken to mean that changes in SBP and DBP values can be used as safe guides to treatment. When BP reductions were expressed as percentages of BP in the control group, regression coefficients were very similar for SBP, DBP, and PP reductions, indicating no preferential relationship of outcome reduction with any BP parameter.
The finding that the relationships of the BP reductions were with the logarithm of the outcome risk ratios adds the important information that progressively greater BP reductions result in progressively lower increments of risk reduction. This parallels the semilogarithmic relation between BP and cardiovascular event rates in the observational studies [81] .
Our finding that not all reductons in cardiovascular outcomes have significant relations with BP decreases is not without precedents. The Blood Pressure Lowering Treatment Trialists' Collaboration reported the relationship of SBP reductions with stroke, CHD, and cardiovascular mortality, but not with heart failure [5] , but subsequently described a positive relation with heart failure as well [82] . Verdecchia et al. [83] also described a positive relation between SBP reduction and both stroke and CHD, but in a subsequent analysis limited to patients with diabetes they confirmed a positive relationship of BP lowering with stroke reduction but not with CHD [84] . The latter metaregression analyses [84] included trials on nonhypertensive patients with diabetes and studies with quite small between-treatment BP differences, and the overall span of SBP and DBP differences was of only 14 and 8 mmHg, respectively. Our findings are in line with what reported in the above-mentioned meta-regression analysis [84] : our analyses have not been limited to patients with diabetes, have only included trials of intentional BP lowering, and the span of SBP and DBP differences was quite wide (40 and 25 mmHg, respectively).
The reasons why CHD events, though significantly reduced by BP lowering, are not reduced in proportion to the BP reduction remain unclear. The lack of correlation is unlikely because of the confounding caused by wide use of statins or aspirin, because the use of these drugs was quite moderate in most of the intentional trials included in our meta-analysis. The lack of correlation may result from the moderate size of the benefit for CHD (16% reduction) and the limited power of meta-regressions to detect small RR changes, although we could find significant correlations between SBP and PP reductions, and an equally small reduction (17%) in the cardiovascular mortality. An alternative explanation is that the maximum risk reduction of CHD occurs after a small BP reduction, and greater BP reductions cannot further decrease CHD, at variance with what is found with stroke, because the bottom autoregulatory threshold for coronary blood flow in hypertension may be set at a higher level than that of the cerebral blood flow [85] .
Strengths and limitations
Our overview and meta-analyses have both strengths and limitations. The major strengths are the number of trials included; the comprehensive inclusion criteria, that is, considering all RCTs that have randomized hypertensive patients to any BP-lowering drug treatment, thus avoiding the biases of strict, but often arbitrary, inclusion criteria; restricting inclusion to the trials predominantly enrolling hypertensive patients, that is, patients for whom antihypertensive therapy is prescribed, and avoiding conditions, such as acute myocardial infarction and heart failure, in which the effects of antihypertensive drugs may be independent of, and in some cases hindered by BP lowering. The above strengths also apply to our meta-regression analyses.
Our analyses also have limitations. In our primary and secondary meta-analyses, we have not only exclusively included trials enrolling hypertensive patients only, but also a few trials also enrolling nonhypertensive patients, provided the proportion of hypertensive patients was at least 40%. However, in order to follow more stringent criteria, we have done sensitivity analyses including only the 38 trials exclusively on hypertensive individuals, finding similar results. The same was the case when trials with lower quality assessment were excluded.
In the meta-analyses comparing the BP-lowering effects on different types of outcome, we have standardized the risk reductions to a 10/5 mmHg SBP/DBP reduction. Our observation that, at variance with other outcomes, CHD and all-cause mortality do not appear to show a significant continuous relation with SBP and DBP reduction may suggest standardization may have induced some bias. However, in placebo-controlled intentional BP-lowering trials, the BP differences actually occurring were extremely close to those used for standardization (by <1 mmHg), and in the intentional BP-lowering trials comparing more with less intense treatment the SBP/DBP differences were of about 7/4 mmHg, thus minimizing the possible bias of extrapolation.
It should finally be mentioned that meta-regression analyses, though instrumental to investigating the quantitative relationships between risk and intervention, are a less safe tool than traditional meta-analyses aiming at estimating the mean effect of a given intervention. Therefore, the evidence provided here by meta-analyses that CHD can be reduced by BP lowering should be considered stronger than the evidence provided by the meta-regressions that this benefit is not related to the BP-lowering extent.
CONCLUSION
Meta-analyses comprehensive of all BP-lowering trials from 1966 to 2013 but specifically involving hypertensive individuals provide the most precise estimate of antihypertensive treatment benefits, these being not only larger for stroke and heart failure, but also significant for CHD and cardiovascular and all-cause mortality. Absolute risk reductions are also substantial, amounting to the prevention of about 28 major cardiovascular events every 1000 hypertensive patients treated for 5 years. Benefits are proportional to the reduction of SBP, DBP, and PP, but the logarithmic relationship implies risk reduction increases to a progressively smaller extent the larger the BP reduction. The data provided can help the scientific societies and health services in providing recommendations and doctors in taking decisions.
